Biomarker-driven treatment strategies for HER2+ G/GEJ junction cancer 

Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the importance of biomarker-driven strategies in HER2+ gastric/gastroesophageal junction (G/GEJ) cancer. Trastuzumab plus chemotherapy has long been effective, now enhanced by pembrolizumab, which was confirmed in the KEYNOTE-811 trial (NCT03615326). Trastuzumab deruxtecan, an antibody-drug conjugate (ADC), uses receptor-ligand binding for targeted cytotoxic delivery. Showing more promising results, this aims to maximize HER2 inhibition and improve outcomes in gastric/gastroesophageal junction cancer. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.